Trading Report: Today, 1,136 Shares of Thermo Fisher Scientific Inc. (TMO) are sold by Tdam USA Inc.

Today, 1,136 Shares of Thermo Fisher Scientific Inc. (TMO) are sold by Tdam USA Inc.

Tdam USA Inc. decreased its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 13.0% during the third quarter, Holdings Channel reports. The fund owned 7,620 shares of the company’s stock after selling 1,136 shares during the period. Tdam USA Inc.’s holdings in Thermo Fisher Scientific were worth $1,212,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. Moors & Cabot Inc. increased its position in shares of Thermo Fisher Scientific by 0.4% in the second quarter. Moors & Cabot Inc. now owns 1,994 shares of the company’s stock worth $294,000 after buying an additional 7 shares during the period. Brown Advisory Securities LLC increased its position in shares of Thermo Fisher Scientific by 0.4% in the second quarter. Brown Advisory Securities LLC now owns 2,388 shares of the company’s stock worth $353,000 after buying an additional 10 shares during the period. Mycio Wealth Partners LLC increased its position in shares of Thermo Fisher Scientific by 1.6% in the second quarter. Mycio Wealth Partners LLC now owns 711 shares of the company’s stock worth $105,000 after buying an additional 11 shares during the period. Parsec Financial Management Inc. increased its position in shares of Thermo Fisher Scientific by 0.6% in the third quarter. Parsec Financial Management Inc. now owns 1,938 shares of the company’s stock worth $308,000 after buying an additional 12 shares during the period. Finally, Quadrant Capital Group LLC increased its position in shares of Thermo Fisher Scientific by 0.6% in the third quarter. Quadrant Capital Group LLC now owns 2,844 shares of the company’s stock worth $442,000 after buying an additional 18 shares during the period. Hedge funds and other institutional investors own 87.45% of the company’s stock.

Thermo Fisher Scientific Inc. (NYSE:TMO) traded up 0.47% on Friday, reaching $144.18. The company’s stock had a trading volume of 804,442 shares. The firm has a market capitalization of $56.95 billion, a P/E ratio of 28.82 and a beta of 1.24. The firm has a 50-day moving average price of $150.43 and a 200 day moving average price of $151.96. Thermo Fisher Scientific Inc. has a 52-week low of $119.75 and a 52-week high of $160.68.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Thursday, October 27th. The company reported $2.03 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.97 by $0.06. The business earned $4.49 billion during the quarter, compared to analyst estimates of $4.39 billion. Thermo Fisher Scientific had a return on equity of 14.95% and a net margin of 11.10%. The company’s revenue was up 8.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.80 earnings per share. Equities analysts anticipate that Thermo Fisher Scientific Inc. will post $8.25 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, January 16th. Stockholders of record on Thursday, December 15th will be issued a $0.15 dividend. The ex-dividend date of this dividend is Tuesday, December 13th. This represents a $0.60 annualized dividend and a dividend yield of 0.42%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 12.00%.

A number of equities analysts recently issued reports on the company. Citigroup Inc. upped their price target on Thermo Fisher Scientific from $160.00 to $182.00 and gave the company a “buy” rating in a report on Friday, July 29th. Jefferies Group reissued a “hold” rating on shares of Thermo Fisher Scientific in a report on Thursday, August 4th. JPMorgan Chase & Co. began coverage on Thermo Fisher Scientific in a report on Thursday, September 22nd. They issued an “overweight” rating and a $180.00 price objective for the company. Zacks Investment Research downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Friday, August 5th. Finally, Leerink Swann began coverage on Thermo Fisher Scientific in a report on Thursday, November 10th. They issued an “outperform” rating and a $175.00 price objective for the company. Two research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $164.37.

In other news, VP Seth H. Hoogasian sold 2,270 shares of the business’s stock in a transaction on Monday, August 29th. The stock was sold at an average price of $152.28, for a total transaction of $345,675.60. Following the sale, the vice president now directly owns 27,384 shares of the company’s stock, valued at $4,170,035.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Daniel P. Shine sold 1,699 shares of the business’s stock in a transaction on Monday, August 29th. The stock was sold at an average price of $152.28, for a total value of $258,723.72. Following the sale, the senior vice president now directly owns 17,437 shares in the company, valued at $2,655,306.36. The disclosure for this sale can be found here. 0.52% of the stock is owned by insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company is a provider of analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. The company operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Related posts

Leave a Comment